31 research outputs found
Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses
Our aim was to study the activity and toxicity of the gemcitabine plus vinorelbine (Gem Vin) combination and to identify the optimal dose. Previously untreated patients aged < 70 years, with stage IV or IIIb (not candidates for radiotherapy) non-small cell lung cancer were eligible. Studied dose-levels of Gem Vin, administered on days 1 and 8 every 3 weeks, were (mg m–2): level I = 1000/25; level II = 1200/25; level III = 1000/30; level IV = 1200/30. A feasibility study was performed at each dose-level, followed by a single-stage phase II study. Dose-level IV was unfeasible because of grade 4 neutropenia. Overall, out of 126 patients enrolled in phase II studies, there were one complete and 32 partial responses (response rate 26%: 95% CI 18–34%). Response rates were 27.9%, 21.4% and 29.3% at levels I, II and III, respectively. The treatment was well tolerated. Toxicity was less frequent and severe at level I. Overall median survival was 33 weeks (95% CI 28–40). Descriptive quality of life analysis showed that patients with a worse baseline global health status score tended to drop out of the study earlier than those with a better score. Gem Vin is feasible at different doses. It is sufficiently active and well tolerated. A phase III study to compare the effect on quality of life of Gem Vin (level I) vs cisplatin-based chemotherapy is ongoing. © 2000 Cancer Research Campaig
Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer
Pain is a highly distressing symptom for patients with advanced cancer. WHO
analgesic ladder is widely accepted as a guideline for its treatment. Our aim was
to describe pain prevalence among patients diagnosed with advanced non-small-cell
lung cancer (NSCLC), impact of pain on quality of life (QoL) and adequacy of pain
management. Data of 1021 Italian patients enrolled in three randomised trials of
chemotherapy for NSCLC were pooled. QoL was assessed by EORTC QLQ-C30 and LC-13.
Analgesic consumption during the 3 weeks following QoL assessment was recorded.
Adequacy of pain management was evaluated by the Pain Management Index (PMI).
Some pain was reported by 74% of patients (42% mild, 24% moderate and 7% severe);
50% stated pain was affecting daily activities (30% a little, 16% quite a bit, 3%
very much). Bone metastases strongly affected presence of pain. Mean global QoL
linearly decreased from 64.9 to 36.4 from patients without pain to those with
severe pain (P<0.001). According to PMI, 616 out of 752 patients reporting pain
(82%) received inadequate analgesic treatment. Bone metastases were associated
with improved adequacy and worst pain with reduced adequacy at multivariate
analysis. In conclusion, pain is common in patients with advanced NSCLC,
significantly affects QoL, and is frequently undertreated. We recommend that:
(i). pain self-assessment should be part of oncological clinical practice; (ii).
pain control should be a primary goal in clinical practice and in clinical
trials; (iii). physicians should receive more training in pain management; (iv).
analgesic treatment deserves greater attention in protocols of anticancer
treatment